Literature DB >> 32195824

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

Murray Esler1, Danielle Esler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32195824     DOI： 10.1097/HJH.0000000000002450

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  107 in total

Review 1.  Medication use during COVID-19: Review of recent evidence.

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

2.  Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19.

Authors:  Henry Sackin
Journal:  Med Hypotheses       Date:  2021-05-12       Impact factor: 1.538

Review 3.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

4.  Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.

Authors:  Emil L Fosbøl; Jawad H Butt; Lauge Østergaard; Charlotte Andersson; Christian Selmer; Kristian Kragholm; Morten Schou; Matthew Phelps; Gunnar H Gislason; Thomas A Gerds; Christian Torp-Pedersen; Lars Køber
Journal:  JAMA       Date:  2020-07-14       Impact factor: 56.272

Review 5. 

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

6.  Acute kidney injury in hospitalized patients with COVID-19: A Portuguese cohort.

Authors:  Joana Gameiro; José Agapito Fonseca; João Oliveira; Filipe Marques; João Bernardo; Claudia Costa; Carolina Carreiro; Sandra Braz; José António Lopes
Journal:  Nefrologia       Date:  2021-05-14       Impact factor: 2.033

7.  Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.

Authors:  Sandeep Singh; Annette K Offringa-Hup; Susan J J Logtenberg; Paul D Van der Linden; Wilbert M T Janssen; Hubertina Klein; Femke Waanders; Suat Simsek; Cornelis P C de Jager; Paul Smits; Machteld van der Feltz; Gerrit Jan Beumer; Christine Widrich; Martijn Nap; Sara-Joan Pinto-Sietsma
Journal:  Hypertension       Date:  2021-06-09       Impact factor: 10.190

8.  Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Authors:  Jordana B Cohen; Thomas C Hanff; Vicente Corrales-Medina; Preethi William; Nicolas Renna; Nelson R Rosado-Santander; Juan E Rodriguez-Mori; Jonas Spaak; Jaime Andrade-Villanueva; Tara I Chang; Alejandro Barbagelata; Carlos E Alfonso; Eduardo Bernales-Salas; Johanna Coacalla; Carlos Augusto Castro-Callirgos; Karen E Tupayachi-Venero; Carola Medina; Renzo Valdivia; Mirko Villavicencio; Charles R Vasquez; Michael O Harhay; Jesse Chittams; Tiffany Sharkoski; James Brian Byrd; Daniel L Edmonston; Nancy Sweitzer; Julio A Chirinos
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-16       Impact factor: 3.738

9.  Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.

Authors:  Alexander T Sandhu; Shun Kohsaka; Shoutzu Lin; Christopher Y Woo; Mary K Goldstein; Paul A Heidenreich
Journal:  Am Heart J       Date:  2021-06-12       Impact factor: 4.749

10.  Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.

Authors:  Axel Bauer; Michael Schreinlechner; Nikolay Sappler; Theresa Dolejsi; Herbert Tilg; Benedikt A Aulinger; Günter Weiss; Rosa Bellmann-Weiler; Christian Adolf; Dominik Wolf; Markus Pirklbauer; Ivo Graziadei; Hannes Gänzer; Christian von Bary; Andreas E May; Ewald Wöll; Wolfgang von Scheidt; Tienush Rassaf; Daniel Duerschmied; Christoph Brenner; Stefan Kääb; Bernhard Metzler; Michael Joannidis; Hans-Ulrich Kain; Norbert Kaiser; Robert Schwinger; Bernhard Witzenbichler; Hannes Alber; Florian Straube; Niels Hartmann; Stephan Achenbach; Michael von Bergwelt-Baildon; Lukas von Stülpnagel; Sebastian Schoenherr; Lukas Forer; Sabine Embacher-Aichhorn; Ulrich Mansmann; Konstantinos D Rizas; Steffen Massberg
Journal:  Lancet Respir Med       Date:  2021-06-11       Impact factor: 30.700
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.